

# **A Novel Synthesis of 2'-Deoxy-2'-[<sup>18</sup>F]fluoro-9-β-D-arabino-furanosylguanine ([<sup>18</sup>F]F-AraG) and associated compounds, and its use for Imaging T Cell Activation with PET**

Stanford researchers have developed a novel PET agent for diseases stemming from T cell origin. The probes help visualize the disease status as well as the progress of therapy. 2-Deoxy-9-β-D-arabino-furanosylguanine (AraG) is a guanosine analog with proven efficacy in the treatment of T cell lymphoblastic disease, such as leukemia. The derivative 2-deoxy-2-fluoro-9-β-D-arabino-furanosylguanine (F-AraG) is known to exhibit selective T-cell toxicity. It is metabolized in a unique fashion by deoxyguanosine kinase and incorporated into mitochondrial DNA. The researchers have developed a novel way to synthesize [<sup>18</sup>F]F-AraG which can be used as a new PET imaging agent for the specific detection of disease of T cell origin. The synthesis method developed here can be used with other PET probes.

## **Applications**

- PET Imaging

## **Advantages**

- Reduced Costs
- Faster 2-step synthesis method
- Use for blood-related diseases, such as leukemia

## **Publications**

- U.S. Patent Application No. [12/875,339](#)

## **Patents**

- Published Application: [20110059014](#)
- Published Application: [20150118157](#)
- Published Application: [20210187133](#)
- Issued: [9,011,817 \(USA\)](#)

## **Innovators**

- Sanjiv Gambhir
- Beverly Mitchell
- Mohammad Namavari

## **Licensing Contact**

### **Jon Gortat**

Licensing & Strategic Alliances Director for Physical Science

[Email](#)